WallStreetZenWallStreetZen

NASDAQ: ECOR
Electrocore Inc Stock Forecast, Predictions & Price Target

Analyst price target for ECOR

Based on 2 analysts offering 12 month price targets for Electrocore Inc.
Min Forecast
$1.25-76.59%
Avg Forecast
$4.13-22.75%
Max Forecast
$7.00+31.09%

Should I buy or sell ECOR stock?

Based on 2 analysts offering ratings for Electrocore Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ECOR stock forecasts and price targets.

ECOR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Bottom 1%
1
BuyReiterates$7.00+31.09%2023-03-09
Brookline Capital
Bottom 26%
26
Strong BuyInitiates Coverage On$1.25-76.59%2023-01-13

1 of 1

Forecast return on equity

Is ECOR forecast to generate an efficient return?
Company
N/A
Industry
0.5%
Market
28.63%

Forecast return on assets

Is ECOR forecast to generate an efficient return on assets?
Company
N/A
Industry
0.21%

ECOR earnings per share forecast

What is ECOR's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.24
Avg 2 year Forecast
-$0.14
Avg 3 year Forecast
-$0.11

ECOR revenue forecast

What is ECOR's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$14.6M+69.52%
Avg 2 year Forecast
$23.0M+167.11%
Avg 3 year Forecast
$32.9M+282.68%
ECOR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ECOR revenue growth forecast

How is ECOR forecast to perform vs Medical Instruments & Supplies companies and vs the US market?
Company
55.71%
Industry
6.46%
Market
8.77%
ECOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ECOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ECOR vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
ECOR$5.34$4.13-22.75%Strong Buy
POAI$0.30$5.00+1,566.67%Strong Buy
EKSO$1.52$9.00+492.11%Buy
MBOT$2.31$20.00+765.80%Strong Buy
FEMY$1.23$7.33+496.18%Strong Buy

Electrocore Stock Forecast FAQ

Is Electrocore Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ECOR) stock is to Strong Buy ECOR stock.

Out of 2 analysts, 1 (50%) are recommending ECOR as a Strong Buy, 1 (50%) are recommending ECOR as a Buy, 0 (0%) are recommending ECOR as a Hold, 0 (0%) are recommending ECOR as a Sell, and 0 (0%) are recommending ECOR as a Strong Sell.

If you're new to stock investing, here's how to buy Electrocore stock.

What is ECOR's earnings growth forecast for 2023-2025?

(NASDAQ: ECOR) Electrocore's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 21.62%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.51%.

Electrocore's earnings in 2023 is -$22,162,000.On average, 3 Wall Street analysts forecast ECOR's earnings for 2023 to be -$1,138,188, with the lowest ECOR earnings forecast at -$1,185,613, and the highest ECOR earnings forecast at -$1,090,764. On average, 3 Wall Street analysts forecast ECOR's earnings for 2024 to be -$663,943, with the lowest ECOR earnings forecast at -$853,641, and the highest ECOR earnings forecast at -$426,821.

In 2025, ECOR is forecast to generate -$521,670 in earnings, with the lowest earnings forecast at -$521,670 and the highest earnings forecast at -$521,670.

What is ECOR's revenue growth forecast for 2023-2025?

(NASDAQ: ECOR) Electrocore's forecast annual revenue growth rate of 55.71% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 6.46%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.77%.

Electrocore's revenue in 2023 is $8,592,000.On average, 2 Wall Street analysts forecast ECOR's revenue for 2023 to be $69,073,784, with the lowest ECOR revenue forecast at $69,050,072, and the highest ECOR revenue forecast at $69,097,497. On average, 2 Wall Street analysts forecast ECOR's revenue for 2024 to be $108,839,228, with the lowest ECOR revenue forecast at $107,179,370, and the highest ECOR revenue forecast at $110,499,085.

In 2025, ECOR is forecast to generate $155,931,756 in revenue, with the lowest revenue forecast at $155,931,756 and the highest revenue forecast at $155,931,756.

What is ECOR's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: ECOR) forecast ROA is N/A, which is lower than the forecast US Medical Instruments & Supplies industry average of 0.21%.

What is ECOR's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ECOR price target, the average ECOR price target is $4.13, with the highest ECOR stock price forecast at $7.00 and the lowest ECOR stock price forecast at $1.25.

On average, Wall Street analysts predict that Electrocore's share price could fall to $4.13 by Mar 9, 2024. The average Electrocore stock price prediction forecasts a potential downside of 22.75% from the current ECOR share price of $5.34.

What is ECOR's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: ECOR) Electrocore's current Earnings Per Share (EPS) is -$4.69. On average, analysts forecast that ECOR's EPS will be -$0.24 for 2023, with the lowest EPS forecast at -$0.25, and the highest EPS forecast at -$0.23. On average, analysts forecast that ECOR's EPS will be -$0.14 for 2024, with the lowest EPS forecast at -$0.18, and the highest EPS forecast at -$0.09. In 2025, ECOR's EPS is forecast to hit -$0.11 (min: -$0.11, max: -$0.11).

What is ECOR's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: ECOR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.